Overview

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Status:
Not yet recruiting

Trial end date:
2025-08-23

Target enrollment:

Participant gender:

Summary

This trial is a combination of trastuzumab and pyrotinib in the treatment of patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy. A total of 50 patients were enrolled in the study design. Preliminary efficacy and safety in patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy.

Phase:

N/A

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab